Abstract | INTRODUCTION: AREAS COVERED: EXPERT OPINION:
GLP-1 receptor agonists result in clinically meaningful weight loss in addition to their beneficial effects on glucose homeostasis. These agents provide substantial clinical benefits for patients compared with sulfonylureas or DPP-4 inhibitors and will, therefore, become one of the major therapeutic choices for patients with T2DM.
|
Authors | Alan J Garber |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 21
Issue 1
Pg. 45-57
(Jan 2012)
ISSN: 1744-7658 [Electronic] England |
PMID | 22111970
(Publication Type: Journal Article, Review)
|
Chemical References |
- Blood Glucose
- GLP1R protein, human
- Glucagon-Like Peptide-1 Receptor
- Hypoglycemic Agents
- Receptors, Glucagon
|
Topics |
- Animals
- Blood Glucose
(drug effects)
- Diabetes Mellitus, Type 2
(drug therapy, physiopathology)
- Drug Approval
- Glucagon-Like Peptide-1 Receptor
- Homeostasis
(drug effects)
- Humans
- Hypoglycemic Agents
(adverse effects, pharmacology, therapeutic use)
- Receptors, Glucagon
(antagonists & inhibitors)
|